Evidence map›Paper›PMID 42455795›Full record

ArticleReproduction & fertility2026

Rapamycin co-exposure fails to reduce cisplatin-induced damage in GC6-spg spermatogonial cell line.

Wafiya Jibrin, Rod T Mitchell, Federica Lopes

Abstract read
In one paragraph

Article in Reproduction & fertility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wafiya JibrinSchool of Medicine, University of Dundee , Dundee, UK.
Rod T MitchellCentre for Reproductive Health, University of Edinburgh , Edinburgh, UK.ORCID 0000-0003-4650-3765
Federica LopesSchool of Medicine, University of Dundee , Dundee, UK.ORCID 0000-0001-5266-9521

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

lay summaryIn the UK, every day about five children receive a diagnosis of cancer. Although the majority (over 80%) will survive, some will become infertile depending on the severity of the treatment received during childhood. Currently, there are no medical treatments available to protect male fertility. This study assessed if rapamycin, a drug currently used to treat other medical conditions, which has been shown in experimental studies to help protect female fertility from cancer treatment, could be used to protect male fertility. Results showed that rapamycin did not prevent overall loss and damage of the cells that will develop into sperm. Further studies are needed to find medical strategies to preserve young boys' fertility.

Indexed as

Antineoplastic AgentsCisplatinSirolimusSpermatogoniaAnimalsCell LineHumansMaleAntineoplastic AgentsCisplatinSirolimuschemotherapycisplatininfertilityrapamycin

Identifiers

PMID42455795
PMCPMC13427972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.